Skip to content

US · MNPR · BIOTECHNOLOGY

Monopar Therapeutics Inc. (MNPR) intrinsic value and stock valuation

$69.00as of 2026-11-21 · Mkt cap 798.59M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Monopar Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values MNPR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MNPR’s statements →

Monopar Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Wilmette, IL 60091 monopartx.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-13.72M
20152025
Free cash flow
-$-12.2M
20152025
Total equity
$137.8M+54.4% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-16.7M-$-16.16M-$-8.83M-$-10.54M-$-9.13M
Net income-$-13.72M-$-15.59M-$-8.4M-$-10.52M-$-9.1M
EPSd-$-1.85M-$-1.36M-$-578.91K-$-827.04K-$-729.75K
Operating cash flow-$-12.2M-$-6.4M-$-7.86M-$-7.23M-$-7.32M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-12.2M-$-6.4M-$-7.86M-$-7.23M-$-7.32M
Total assets$140.7M$60.3M$7.35M$13.2M$20.5M
Total debt$150K$0.00$0.00$10K$0.00
Net debt-$-61.68M-$-45.82M-$-7.27M-$-8.18M-$-20.3M
Total equity$137.8M$55M$5.59M$10.1M$18.9M
Cash and short-term investments$140.4M$60.2M$7.27M$13.1M$20.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$9.9B$13M$5.6M$7.59M$6.49M
Selling, general and administrative expenses$6.8B$3.16M$3.23M$2.95M$2.63M
Other expenses-$-16.69B$0.00$0.00$0.00$0.00
Operating expenses$16.7M$16.2M$8.83M$10.5M$9.13M
Cost and expenses$16.7M$16.2M$8.83M$10.5M$9.13M
Interest income$2.99M$400K$430K$20K$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-13.72M-$-15.59M-$-8.4M-$-10.52M-$-9.1M
Operating income-$-16.7M-$-16.16M-$-8.83M-$-10.54M-$-9.13M
Total other income/expenses, net$2.99M$580K$430K$20K$20K
Income before tax-$-13.72M-$-15.59M-$-8.4M-$-10.52M-$-9.1M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-13.72M-$-15.59M-$-8.4M-$-10.52M-$-9.1M
Weighted average shares outstanding$7.41M$11.4M$14.5M$12.7M$12.5M
Weighted average diluted shares outstanding$7.41M$11.5M$14.5M$12.7M$12.5M
Balance sheet
20252024202320222021
Cash and short-term investments$140.4M$60.2M$7.27M$13.1M$20.3M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$140.5M$60.3M$7.33M$13.2M$20.5M
Property, plant and equipment, net$250K$0.00$10K$60K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$250K$0.00$10K$60K$0.00
Total assets$140.7M$60.3M$7.35M$13.2M$20.5M
Accounts payable$2.74M$2.25M$1.76M$3.13M$1.58M
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.74M$5.25M$1.76M$3.13M$1.58M
Long-term debt$150K$0.00$0.00$10K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$150K$0.00$0.00$10K$0.00
Capital lease obligations$150K$0.00$0.00$10K$0.00
Total liabilities$2.89M$5.25M$1.76M$3.14M$1.58M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-89.51M-$-75.79M-$-60.21M-$-51.8M-$-41.29M
Accumulated other comprehensive income (loss)$130K$40K-$-10K$10K-$0.00
Total equity$137.8M$55M$5.59M$10.1M$18.9M
Total investments$78.6M$14.4M$0.00$4.93M$0.00
Total debt$150K$0.00$0.00$10K$0.00
Net debt-$-61.68M-$-45.82M-$-7.27M-$-8.18M-$-20.3M
Cash flow statement
20252024202320222021
Net income-$-13.72M-$-15.59M-$-8.4M-$-10.52M-$-9.1M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$4.84M$1.14M$1.9M$1.64M$1.47M
Change in working capital-$-2.61M$3.49M-$-1.35M$1.65M$320K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$390K$510K-$-1.33M$1.48M$400K
Net cash provided by operating activities-$-12.2M-$-6.4M-$-7.86M-$-7.23M-$-7.32M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-63.45M-$-14.34M$4.93M-$-4.92M$0.00
Common stock issued$127.7M$59.4M$2.07M$110K$10.9M
Common stock repurchased-$-35M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$91.6M$59.3M$2.03M$30K$10.9M
Net change in cash$16M$38.6M-$-920K-$-12.12M$3.57M
Cash at end of period$61.8M$45.8M$7.27M$8.19M$20.3M
Operating cash flow-$-12.2M-$-6.4M-$-7.86M-$-7.23M-$-7.32M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-12.2M-$-6.4M-$-7.86M-$-7.23M-$-7.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Monopar Therapeutics Inc.

        Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

        CEO
        Chandler D. Robinson
        Employees
        22
        Beta
        1.48

        Explore

        Frequently asked questions

        What is the intrinsic value of Monopar Therapeutics Inc. (MNPR)?

        InvestorsCraft does not currently publish an intrinsic value for MNPR. How the IC value is calculated.

        Is MNPR undervalued?

        InvestorsCraft does not publish an undervaluation signal for MNPR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.